Targeting HER2 as an anchor to modulate adaptive and innate immunity can redirect NK and CD8 T cells to target tumors, reshaping the tumor microenvironment and making “cold” tumors “hot” tumors (NCT04143711) (22). The gene discussed is ERBB2; the disease is neoplasm.